STAR-0310: A Monoclonal Antibody OX40 Antagonist
Time: 12:15 pm
day: Day One Discovery Track AM
Details:
- OX40 inhibition is a clinically validated mechanism for the treatment of AD
- Using half-life extension technology with the aim of durable efficacy with less frequent dosing every 2-3 months, STAR0310 is designed with the potential to be a first-choice treatment that reduces disease and treatment burden to help normalize the lives of people with atopic dermatitis
- STAR-0310 has a potential best-in-class profile with a high potency, potential for favorable safety and tolerability profile with low T-cell depletion from ADCC or possible on-target cellular toxicity, and less frequent dosing
- How this MoA has utility across the spectrum of dermatology diseases
